Supplementary materials

Supplement to:

Vos JR, Fakkert IE, de Hullu JA, van Altena AM, Sie AS, Ouchene H, Willems RW, Nagtegaal ID, Jongmans MCJ, Mensenkamp AR, Woldringh GH, Bulten J, Leter EM, Kets CM, Simons M, Ligtenberg MJL, Hoogerbrugge N on behalf of the OPA working group. *Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition.* J Natl Cancer Inst. 2019.

Supplementary Table 1. Characteristics of the 2 OC patients with only a variant of unknown significance identified with the universal tumor *BRCA1/2* workflow

Gene	Variant c.*	Variant p.*	Age OC, y	OC histology	FIGO stage
BRCA2	c.7463G>A	p.(Arg2488Lys)	46	HGS	n/a
BRCA2	c.575T>C	p.(Met192Thr)	68	HGS	n/a

* Variant nomenclature according to HGVS guidelines (varnomen.hgvs.org). FIGO, International Federation of Gynecology and Obstetrics; OC, epithelial ovarian cancer; HGS, high grade serous; n/a, not available.

Supplementary Figure 1. Overview of the study cohort and data collection over time



Supplementary Figure 2. Age at ovarian cancer diagnosis by *BRCA1/2* tumor and germline (hereditary) status

The boxplots indicate the median and (interquartile) range of the age at diagnosis.